Hodgkin Lymphoma – An Overview of the Disease and Clinical Pipeline

Introduction

Hodgkin lymphoma (HL), also known as B-cell Hodgkin lymphoma, is a cancer of the lymphatic system. It is a rare disease, accounting for only about 0.5% of all new cancer cases each year in the United States. However, advances in research have led to the development of various treatment options.

Clinical Pipeline

The current clinical pipeline for HL includes both T cell and B cell lymphoma therapies. These can be further broken down into:

T Cell Lymphoma Market

T cell lymphoma is a type of non-Hodgkin lymphoma that develops in mature T cells. The current market of T cell lymphoma therapies includes:

Adcetris (brentuximab vedotin)
Zolinza (vorinostat)
Ibrutinib

T Cell Lymphoma Clinical Pipeline Report

The clinical pipeline for T cell lymphoma includes a number of potential therapies, including:

Alisertib
Belinostat
Carmustine
Crizotinib Hydrochloride
Fludarabine phosphate

B Cell Lymphoma Market

B cell lymphoma develops in the white blood cells known as B cells, and can be further categorized as classical HL or nodular lymphocyte-predominant HL. The current market of B cell lymphoma therapies includes:

Adcetris (brentuximab vedotin)
Keytruda (pembrolizumab)
Opdivo (nivolumab)

B Cell Lymphoma Clinical Pipeline Report

The clinical pipeline for B cell lymphoma includes a number of potential therapies, including:

Brentuximab
Escalated BEACOPP
Ibrutinib
Nivolumab
Pembrolizumab
Panobinostat

Conclusion

While HL is a rare disease, it has received significant attention in the research community due to the development of novel therapies and treatment options. With the continued development of clinical pipelines and further research, it is likely that positive outcomes will be observed for patients in the future.

Originally Post From https://www.openpr.com/news/3545518/t-cell-lymphoma-market-growth-insight-share-size-major

T-cell Lymphoma Market Growth Insight Share Size Major